US-based medical device firm HLT has started patient enrolment in a feasibility clinical study (RADIANT) of its Meridian transcatheter aortic valve and Pathfinder II delivery system to treat severe aortic stenosis.

The Meridian transcatheter aortic valve is designed to adapt to the heart's natural structure and the Pathfinder II delivery system allows control of the valve placement in a heart prior to release.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The prospective, non-randomised, single-arm, multicentre RADIANT trial will evaluate the safety and performance outcomes of the valve and system in 20 patients who are at high risk for surgery.

HLT general manager Kevin Bassett said: "The RADIANT clinical study will provide evidence regarding the safety and performance of a third-generation transcatheter aortic valve replacement therapy.

"We're delighted to partner in the study with outstanding clinicians at the Quebec Heart and Lung Institute as well as the Sunnybrook Health Science Centre in Toronto."

See Also:

"The RADIANT clinical study will provide evidence regarding the safety and performance of a third-generation transcatheter aortic valve replacement therapy."

The ideal positioning of a valve is expected to aid in good hemodynamics, decrease leakage around the valve's base and promote optimal patient outcomes.  

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The self-expanding Meridian transcatheter aortic valve features a flexible wire to support its leaflets to enable good flow characteristics as well as minimise stress on the tissue of leaflet for long-term performance.

The trial's endpoint will examine all-cause mortality at 30 days following the implant of the Meridian valve.

Patient follow-ups will be performed at one, six and 12 months and also annually up to five years.

Image: Meridian valve. Photo: courtesy of HLT.